Morgan Stanley’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Morgan Stanley’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-156	Closed	-$406	–	8093
2024 Q1	$406	Sell	156 -90	-37%	-$251	﹤0.01%	7257
2023 Q4	$888	Buy	246 +123	+100%	+$485	﹤0.01%	7218
2023 Q3	$637	Hold	123	–	–	﹤0.01%	7283
2023 Q2	$1.05K	Buy	123 +99	+413%	+$1.02K	﹤0.01%	7288
2023 Q1	$279	Sell	24 -3	-11%	-$40	﹤0.01%	7493
2022 Q4	$386	Hold	27	–	–	﹤0.01%	7585
2022 Q3	$1K	Sell	27 -893	-97%	-$62.1K	﹤0.01%	7649
2022 Q2	$78K	Buy	920 +61	+7%	+$5.22K	﹤0.01%	6400
2022 Q1	$129K	Sell	859 -55	-6%	-$12.7K	﹤0.01%	6164
2021 Q4	$273K	Buy	914 +288	+46%	+$110K	﹤0.01%	5894
2021 Q3	$244K	Buy	626 +578	+1,204%	+$246K	﹤0.01%	5893
2021 Q2	$20K	Buy	+48	New	+$20.8K	﹤0.01%	7016

Other funds holding FNCH

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Morgan Stanley's FNCH Position: Q2 2024 in Review

Morgan Stanley sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 156 shares — an estimated $406 sold.

Morgan Stanley first reported a position in FNCH in Q2 2021 and held it in 12 quarters. The position peaked at $273K in Q4 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

Morgan Stanley reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Morgan Stanley sold 156 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $406.
Morgan Stanley first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
Morgan Stanley's Finch Therapeutics Group, Inc. Common Stock position peaked at $273K in Q4 2021.
1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.